Ataraxis AI

📍 New York, United States🗓 Founded 2023👥 40 employees💰 Last funded Feb 2026
Biotechnology🌐 ataraxis.ai
Website LinkedIn
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
4
Total investors
3
Early stage
1
Mid stage
0
Late stage
2023
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
2
Germany
1
Poland
1
Investor activity2024–2026 · investors recorded per year
202412025220261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Ataraxis AI?
Ataraxis AI has 4 investors on record on gritt.io, including 3 early-stage backers, 1 mid-stage.
When did Ataraxis AI last raise funding?
The most recent investment in Ataraxis AI recorded on gritt.io was in February 2026.
When was Ataraxis AI founded?
Ataraxis AI was founded in 2023.
What industry is Ataraxis AI in?
Ataraxis AI operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Ataraxis AI based?
Ataraxis AI is headquartered in New York, United States.